Cell Line Origin
Human Caucasian lung large cell carcinoma,drug-resistant revertant
Cell Line Description
The revertant lung cancer cell line COR-L23/R23- was generated by growing the doxorubicin-selected, resistant variant COR-L23/R (Sigma Catalogue number. 96042339) without drug exposure for 24-28 weeks. The cell line, also known as COR-L23/Rev, overexpresses multidrug resistance -associated protein (MRP), but to a lesser extent than the parent line. It was shown that the cell line has the ability to recover quickly, similar levels of MRP expression and resistance as COR-L23/R after a transient exposure to the MDR-drugs doxorubicin and vincristine.
Application
Studies on lung cancer, drug-resistance analysis
DNA Profile
STR-PCR Data: Amelogenin: X
CSF1PO: 11
D13S317: 10,11
D16S539: 11,13
D5S818: 10,12
D7S820: 9
THO1: 9
TPOX: 8,11
vWA: 19
Culture Medium
RPMI 1640 +2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Subculture Routine
Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
biological source: human unknown/unspecified. growth mode: Adherent. karyotype: Not specified. morphology: Epithelial. products: Not specified. receptors: Not specified. technique(s): cell culture | mammalian: suitable. relevant disease(s): cancer. shipped in: dry ice. storage temp.: −. 196°C.- UPC:
- 51161702
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 96042337-1VL
